Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 30, 2025 21:00 ET | Source: Teva Pharmaceutical Industries Ltd

Teva Presents Latest Schizophrenia Portfolio Data Including Real-World Outcomes with UZEDY® (risperidone) Showing Lower Rates of and Longer Time to Relapse Compared to Oral Treatment Options and New Phase 3 SOLARIS Data Showing No Incidence of PDSS with TEV-'749 (olanzapine) to Date

Real-world claims studies evaluating UZEDY® (risperidone) also show improved adherence and persistence rates, fewer inpatient, outpatient and emergency department (ED) visits versus second-generation...
May 27, 2025 10:56 ET | Source: Research and Markets

Schizophrenia Drugs Market Research Report 2025-2035: Advances in Antipsychotic Drug Development, Increasing Prevalence, & Greater Awareness and Access to Mental Health Care Bolster Growth

Dublin, May 27, 2025 (GLOBE NEWSWIRE) -- The "Schizophrenia Drugs Market - A Global and Regional Analysis: Focus on Country and Regional Analysis - Analysis and Forecast, 2025-2035" report has been...
April 30, 2025 11:09 ET | Source: Research and Markets

Bipolar Disorder Pipeline Insight 2025 | In-Depth Review of Over 20 Pipeline Drugs

Dublin, April 30, 2025 (GLOBE NEWSWIRE) -- The "Bipolar Disorder (Manic Depression)- Pipeline Insight, 2025" has been added to ResearchAndMarkets.com's offering. The report offers an extensive...
October 14, 2024 12:09 ET | Source: Research and Markets

2024 Research Report | Antipsychotic Drugs Market Poised for Significant Growth by 2030, Advances in Mental Health Treatment Drive Demand

Dublin, Oct. 14, 2024 (GLOBE NEWSWIRE) -- The "Antipsychotic Drugs - Market Insights, Competitive Landscape, and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's...
January 24, 2019 07:00 ET | Source: Streetwise Reports Llc

Streetwise Reports Examines the Commercial Launch Planned for Schizophrenia Drug

SAN FRANCISCO, Jan. 24, 2019 (GLOBE NEWSWIRE) -- DURECT Corp. (DRRX:NASDAQ), a biopharmaceutical company, noted that Indivior Plc announced that it will launch in the U.S. its drug for the treatment...